Payment overview · 2025
General Payments
$628.26
27 reported records · 11 companies
Healthcare provider profile · identity verified
Badar Anwar, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HENDERSON, NV · NPI 1861443640
Verified facts
What the public records show
CMS Open Payments records show Badar Anwar, M.D. received $628.26 in general payments during 2025 across 27 reported records.
Amgen Inc. accounted for 27.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $173.02 | 27.5% | 9 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $124.85 | 19.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $101.36 | 16.1% | 5 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $72.92 | 11.6% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $45.23 | 7.2% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $21.00 | 3.3% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $20.94 | 3.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.61 | 3.1% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.86 | 3.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.48 | 2.5% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $14.99 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $628.26 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $173.02 | 9 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $124.85 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $78.89 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $78.37 | 4 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $72.92 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $25.28 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $22.47 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $20.94 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $20.94 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.95 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.95 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.48 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $14.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 139 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
139 | 34 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 945 | 277 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 773 | 236 |
| Ezetimibe | Ezetimibe | 514 | 163 |
| Losartan Potassium | Losartan Potassium | 511 | 150 |
| Amlodipine Besylate | Amlodipine Besylate | 501 | 157 |
| Mounjaro | Tirzepatide | 451 | 70 |
| Hydrochlorothiazide | Hydrochlorothiazide | 302 | 87 |
| Levothyroxine Sodium | Levothyroxine Sodium | 297 | 85 |
| Lisinopril | Lisinopril | 294 | 86 |
| Tamsulosin Hcl | Tamsulosin Hcl | 225 | 69 |
| Tizanidine Hcl | Tizanidine Hcl | 214 | 90 |
| Metformin Hcl | Metformin Hcl | 203 | 72 |
| Metoprolol Succinate | Metoprolol Succinate | 203 | 65 |
| Omeprazole | Omeprazole | 189 | 59 |
| Fluticasone Propionate | Fluticasone Propionate | 167 | 96 |
| Pantoprazole Sodium | Pantoprazole Sodium | 165 | 53 |
| Metformin Hcl Er | Metformin Hcl | 163 | 61 |
| Furosemide | Furosemide | 157 | 53 |
| Escitalopram Oxalate | Escitalopram Oxalate | 148 | 49 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 144 | 39 |
| Farxiga | Dapagliflozin Propanediol | 139 | 34 |
| Sertraline Hcl | Sertraline Hcl | 132 | 29 |
| Eliquis | Apixaban | 129 | 40 |
| Potassium Chloride | Potassium Chloride | 129 | 50 |
| Allopurinol | Allopurinol | 126 | 37 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 124 | 43 |
| Meloxicam | Meloxicam | 120 | 58 |
| Indapamide | Indapamide | 114 | 38 |
| Gabapentin | Gabapentin | 113 | 39 |
| Spironolactone | Spironolactone | 108 | 38 |
| Trazodone Hcl | Trazodone Hcl | 107 | 35 |
| Atenolol | Atenolol | 103 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 95 | 29 |
| Finasteride | Finasteride | 94 | 30 |
| Pioglitazone Hcl | Pioglitazone Hcl | 93 | 26 |
| Alprazolam | Alprazolam | 91 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 91 | 26 |
| Montelukast Sodium | Montelukast Sodium | 87 | 30 |
| Mirtazapine | Mirtazapine | 76 | 24 |
| Chlorthalidone | Chlorthalidone | 69 | 22 |
| Prednisone | Prednisone | 69 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 68 | 24 |
| Synthroid | Levothyroxine Sodium | 66 | 15 |
| Famotidine | Famotidine | 65 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 64 | 26 |
| Carvedilol | Carvedilol | 62 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 60 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 59 | 36 |
| Ozempic | Semaglutide | 53 | 16 |
| Alendronate Sodium | Alendronate Sodium | 52 | 18 |
| Jardiance | Empagliflozin | 50 | 18 |
| Nifedipine Er | Nifedipine | 50 | 16 |
| Felodipine Er | Felodipine | 49 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 49 | 17 |
| Baclofen | Baclofen | 48 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | 15 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 47 | 14 |
| Pregabalin | Pregabalin | 40 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 38 | 12 |
| Clonazepam | Clonazepam | 38 | suppressed |
| Irbesartan | Irbesartan | 38 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 38 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Glipizide | Glipizide | 36 | 11 |
| Trulicity | Dulaglutide | 36 | 11 |
| Glimepiride | Glimepiride | 35 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 35 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 33 | 32 |
| Repatha Syringe | Evolocumab | 33 | suppressed |
| Simvastatin | Simvastatin | 33 | suppressed |
| Lorazepam | Lorazepam | 32 | suppressed |
| Valsartan | Valsartan | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 28 |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | 16 |
| Breyna | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | suppressed |
| Kerendia | Finerenone | 22 | suppressed |
| Repatha Sureclick | Evolocumab | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 17 |
| Colchicine | Colchicine | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Celecoxib | Celecoxib | 18 | 12 |
| Testosterone | Testosterone | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Calcitriol | Calcitriol | 16 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Invokana | Canagliflozin | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | 11 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Praluent Pen | Alirocumab | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Minoxidil | Minoxidil | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Buprenorphine | Buprenorphine | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Saxagliptin-Metformin Er | Saxagliptin Hcl/Metformin Hcl | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Acarbose | Acarbose | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Np Thyroid | Thyroid,pork | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $628.26 · 27 records | Amgen Inc. | AIRSUPRA, AREXVY, FARXIGA, Fluad, Flucelvax, GEMTESA, LEQVIO, NEXLETOL, OTEZLA, REPATHA, REXULTI, SHINGRIX, TRELEGY ELLIPTA, Veozah, XIFAXAN, ZORYVE | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error